Cardioembolic and Small Vessel Disease Stroke Show Differences in Associations between Systemic C3 Levels and Outcome

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Stokowska, Anna ^a   Olsson, Sandra ^a   Holmegaard, Lukas ^a   Jood, Katarina ^a   Blomstrand, Christian ^a   Jern, Christina ^a   Pekna, Marcela ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3A;

ADULT; ARTICLE; BRAIN ISCHEMIA; CARDIOEMBOLIC STROKE; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL;

C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; COMPLEMENT ACTIVATION; COMPLEMENT C3A; EMBOLISM; FEMALE; HUMANS; MALE; MICROVESSELS; MIDDLE AGED; MULTIVARIATE ANALYSIS; STROKE; TREATMENT OUTCOME;

EID: 84882627221     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072133     Document Type: Article

References (47)

1. Iadecola C, Anrather J, (2011) Stroke research at a crossroad: asking the brain for directions. Nat Neurosci 14: 1363-1368.
2. Worthmann H, Tryc AB, Goldbecker A, Ma YT, Tountopoulou A, et al. (2010) The temporal profile of inflammatory markers and mediators in blood after acute ischemic stroke differs depending on stroke outcome. Cerebrovasc Dis 30: 85-92.
3. Stevens B, Allen NJ, Vazquez LE, Howell GR, Christopherson KS, et al. (2007) The classical complement cascade mediates CNS synapse elimination. Cell 131: 1164-1178.
4. Berg A, Zelano J, Stephan A, Thams S, Barres BA, et al. (2012) Reduced removal of synaptic terminals from axotomized spinal motoneurons in the absence of complement C3. Exp Neurol 237: 8-17.
5. Rahpeymai Y, Hietala MA, Wilhelmsson U, Fotheringham A, Davies I, et al. (2006) Complement: a novel factor in basal and ischemia-induced neurogenesis. EMBO J 25: 1364-1374.
6. Shinjyo N, Stahlberg A, Dragunow M, Pekny M, Pekna M, (2009) Complement-derived anaphylatoxin C3a regulates in vitro differentiation and migration of neural progenitor cells. Stem Cells 27: 2824-2832.
7. Mukherjee P, Pasinetti GM, (2001) Complement anaphylatoxin C5a neuroprotects through mitogen-activated protein kinase-dependent inhibition of caspase 3. J Neurochem 77: 43-49.
8. van Beek J, Nicole O, Ali C, Ischenko A, MacKenzie ET, et al. (2001) Complement anaphylatoxin C3a is selectively protective against NMDA-induced neuronal cell death. Neuroreport 12: 289-293.
9. Benoit ME, Tenner AJ, (2011) Complement protein C1q-mediated neuroprotection is correlated with regulation of neuronal gene and microRNA expression. J Neurosci 31: 3459-3469.
10. Arumugam TV, Magnus T, Woodruff TM, Proctor LM, Shiels IA, et al. (2006) Complement mediators in ischemia-reperfusion injury. Clin Chim Acta 374: 33-45.
11. Costa C, Zhao L, Shen Y, Su X, Hao L, et al. (2006) Role of complement component C5 in cerebral ischemia/reperfusion injury. Brain Res 1100: 142-151.
12. De Simoni MG, Storini C, Barba M, Catapano L, Arabia AM, et al. (2003) Neuroprotection by complement (C1) inhibitor in mouse transient brain ischemia. J Cereb Blood Flow Metab 23: 232-239.
13. Huang J, Kim LJ, Mealey R, Marsh HC Jr, Zhang Y, et al. (1999) Neuronal protection in stroke by an sLex-glycosylated complement inhibitory protein. Science 285: 595-599.
14. Mocco J, Mack WJ, Ducruet AF, Sosunov SA, Sughrue ME, et al. (2006) Complement component C3 mediates inflammatory injury following focal cerebral ischemia. Circ Res 99: 209-217.
15. Pavlovski D, Thundyil J, Monk PN, Wetsel RA, Taylor SM, et al. (2012) Generation of complement component C5a by ischemic neurons promotes neuronal apoptosis. FASEB J 26: 3680-3690.
16. Howell GR, Macalinao DG, Sousa GL, Walden M, Soto I, et al. (2011) Molecular clustering identifies complement and endothelin induction as early events in a mouse model of glaucoma. J Clin Invest 121: 1429-1444.
17. Ramaglia V, Hughes TR, Donev RM, Ruseva MM, Wu X, et al. (2012) C3-dependent mechanism of microglial priming relevant to multiple sclerosis. Proc Natl Acad Sci U S A 109: 965-970.
18. Pedersen ED, Loberg EM, Vege E, Daha MR, Maehlen J, et al. (2009) In situ deposition of complement in human acute brain ischaemia. Scand J Immunol 69: 555-562.
19. Lindsberg PJ, Ohman J, Lehto T, Karjalainen-Lindsberg ML, Paetau A, et al. (1996) Complement activation in the central nervous system following blood-brain barrier damage in man. Ann Neurol 40: 587-596.
20. Cervera A, Planas AM, Justicia C, Urra X, Jensenius JC, et al. (2010) Genetically-defined deficiency of mannose-binding lectin is associated with protection after experimental stroke in mice and outcome in human stroke. PLoS One 5: e8433 doi: 8410.1371/journal.pone.0008433.
21. Osthoff M, Katan M, Fluri F, Schuetz P, Bingisser R, et al. (2011) Mannose-binding lectin deficiency is associated with smaller infarction size and favorable outcome in ischemic stroke patients. PLoS One 6: e21338 doi: 21310.21371/journal.pone.0021338.
22. Mocco J, Wilson DA, Komotar RJ, Sughrue ME, Coates K, et al. (2006) Alterations in plasma complement levels after human ischemic stroke. Neurosurgery 59: 28-33.
23. Szeplaki G, Szegedi R, Hirschberg K, Gombos T, Varga L, et al. (2009) Strong complement activation after acute ischemic stroke is associated with unfavorable outcomes. Atherosclerosis 204: 315-320.
24. Tamam Y, Iltumur K, Apak I, (2005) Assessment of acute phase proteins in acute ischemic stroke. Tohoku J Exp Med 206: 91-98.
25. Olsson S, Stokowska A, Holmegaard L, Jood K, Blomstrand C, et al. (2011) Genetic variation in complement component C3 shows association with ischaemic stroke. Eur J Neurol 18: 1272-1274.
26. Stokowska A, Olsson S, Holmegaard L, Jood K, Blomstrand C, et al. (2011) Plasma C3 and C3a levels in cryptogenic and large-vessel disease stroke: associations with outcome. Cerebrovasc Dis 32: 114-122.
27. Jood K, Ladenvall C, Rosengren A, Blomstrand C, Jern C, (2005) Family history in ischemic stroke before 70 years of age: the Sahlgrenska Academy Study on Ischemic Stroke. Stroke 36: 1383-1387.
28. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, et al. (1993) Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24: 35-41.
29. Ladenvall C, Jood K, Blomstrand C, Nilsson S, Jern C, et al. (2006) Serum C-reactive protein concentration and genotype in relation to ischemic stroke subtype. Stroke 37: 2018-2023.
30. Pedersen ED, Waje-Andreassen U, Vedeler CA, Aamodt G, Mollnes TE, (2004) Systemic complement activation following human acute ischaemic stroke. Clin Exp Immunol 137: 117-122.
31. Jung KW, Shon YM, Yang DW, Kim BS, Cho AH, (2012) Coexisting carotid atherosclerosis in patients with intracranial small- or large-vessel disease. J Clin Neurol 8: 104-108.
32. Buono C, Come CE, Witztum JL, Maguire GF, Connelly PW, et al. (2002) Influence of C3 deficiency on atherosclerosis. Circulation 105: 3025-3031.
33. Persson L, Boren J, Nicoletti A, Hansson GK, Pekna M, (2005) Immunoglobulin treatment reduces atherosclerosis in apolipoprotein E-/- low-density lipoprotein receptor-/- mice via the complement system. Clin Exp Immunol 142: 441-445.
34. Persson L, Boren J, Robertson AK, Wallenius V, Hansson GK, et al. (2004) Lack of complement factor C3, but not factor B, increases hyperlipidemia and atherosclerosis in apolipoprotein E-/- low-density lipoprotein receptor-/- mice. Arterioscler Thromb Vasc Biol 24: 1062-1067.
35. Leung VW, Yun S, Botto M, Mason JC, Malik TH, et al. (2009) Decay-accelerating factor suppresses complement C3 activation and retards atherosclerosis in low-density lipoprotein receptor-deficient mice. Am J Pathol 175: 1757-1767.
36. Lewis MJ, Malik TH, Fossati-Jimack L, Carassiti D, Cook HT, et al. (2012) Distinct roles for complement in glomerulonephritis and atherosclerosis revealed in mice with a combination of lupus and hyperlipidemia. Arthritis Rheum 64: 2707-2718.
37. Lewis RD, Perry MJ, Guschina IA, Jackson CL, Morgan BP,et al. CD55 deficiency protects against atherosclerosis in ApoE-deficient mice via C3a modulation of lipid metabolism. Am J Pathol 179: 1601-1607.
38. Hoffmeister HM, Ehlers R, Buttcher E, Kazmaier S, Szabo S, et al. (2002) Comparison of C-reactive protein and terminal complement complex in patients with unstable angina pectoris versus stable angina pectoris. Am J Cardiol 89: 909-912.
39. Kostner KM, Fahti RB, Case C, Hobson P, Tate J, et al. (2006) Inflammation, complement activation and endothelial function in stable and unstable coronary artery disease. Clin Chim Acta 365: 129-134.
40. Laine P, Pentikainen MO, Wurzner R, Penttila A, Paavonen T, et al. (2002) Evidence for complement activation in ruptured coronary plaques in acute myocardial infarction. Am J Cardiol 90: 404-408.
41. Oksjoki R, Kovanen PT, Meri S, Pentikainen MO, (2007) Function and regulation of the complement system in cardiovascular diseases. Front Biosci 12: 4696-4708.
42. Palikhe A, Sinisalo J, Seppanen M, Haario H, Meri S, et al. (2007) Serum complement C3/C4 ratio, a novel marker for recurrent cardiovascular events. Am J Cardiol 99: 890-895.
43. Speidl WS, Exner M, Amighi J, Kastl SP, Zorn G, et al. (2005) Complement component C5a predicts future cardiovascular events in patients with advanced atherosclerosis. Eur Heart J 26: 2294-2299.
44. Speidl WS, Katsaros KM, Kastl SP, Zorn G, Huber K, et al. (2010) Coronary late lumen loss of drug eluting stents is associated with increased serum levels of the complement components C3a and C5a. Atherosclerosis 208: 285-289.
45. Smith CJ, Emsley HC, Gavin CM, Georgiou RF, Vail A, et al. (2004) Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome. BMC Neurol 4: 2.
46. Haskard DO, Boyle JJ, Mason JC, (2008) The role of complement in atherosclerosis. Curr Opin Lipidol 19: 478-482.
47. Dressel A, (2011) Is stroke etiology a determining factor for the pattern of secondary immune alterations? Cerebrovasc Dis 32: 123.